The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of NASDAQ? listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Inception Date: 05/02/2001
Primary Benchmark: NASDAQ Biotechnology TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.47%
Management Expense Ratio: 0.47 %
|GILD||Gilead Sciences Inc.||8.22 %|
|AMGN||Amgen Inc.||8.17 %|
|BIIB||Biogen Inc.||7.01 %|
|CELG||Celgene Corporation||6.75 %|
|VRTX||Vertex Pharmaceuticals Incorporated||4.49 %|
|REGN||Regeneron Pharmaceuticals Inc.||4.47 %|
|ILMN||Illumina Inc.||3.87 %|
|ALXN||Alexion Pharmaceuticals Inc.||3.57 %|
|MYL||Mylan N.V.||2.94 %|
|INCY||Incyte Corporation||2.44 %|
|PSCH||PowerShares S&P SmallCap Healt..||0.29 %||
|BBH||VanEck Vectors Biotech ETF||0.35 %||
|PPH||VanEck Vectors Pharmaceutical ..||0.35 %||
|PTH||PowerShares DWA Healthcare Mom..||0.60 %||
|CNCR||Loncar Cancer Immunotherapy ET..||0.79 %||
|BTEC||Principal Healthcare Innovator..||0.42 %||
|GNRX||VanEck Vectors Generic Drugs E..||0.55 %||
|FTXH||First Trust Nasdaq Pharmaceuti..||0.60 %||
|SLIM||The Obesity ETF||0.50 %||
|LNGR||Global X Longevity Thematic ET..||0.52 %||
|Market Performance vs.
|Market Performance vs. Exchange (NASDAQ Global Market)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||24.51%||9%||F||55%||F|
|Risk Adjusted Return||59.75%||55%||F||62%||D-|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.